发明名称 |
COMBINATION OF IMMUNOMODULATORY AGENT WITH PD-1 or PD-L1 CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER |
摘要 |
Methods for treating cancer include administering a therapeutically effective amount of an immunomodulatory agent such as interferon gamma 1b in combination with a therapeutically effective amount of a PD-1 checkpoint inhibitor such as nivolumab or pembrolizumab or a therapeutically effective amount of a PD-L1 checkpoint inhibitor. |
申请公布号 |
US2017021019(A1) |
申请公布日期 |
2017.01.26 |
申请号 |
US201615216585 |
申请日期 |
2016.07.21 |
申请人 |
Zibelman Matthew;Plimack Elizabeth;Grahn Amy;Devane John Gerard;Sherman Jeffrey W. |
发明人 |
Zibelman Matthew;Plimack Elizabeth;Grahn Amy;Devane John Gerard;Sherman Jeffrey W. |
分类号 |
A61K39/395;C07K16/28;A61K38/21 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for treating cancer, comprising administering to a patient in need thereof
(a) a therapeutically effective amount of an immunomodulatory agent, and (b) a therapeutically effective amount of a PD-1 checkpoint inhibitor and/or a therapeutically effective amount of PD-L1 checkpoint inhibitor. |
地址 |
Philadelphia PA US |